Drugs / Piperacillin/tazobactam
last change Mar 2023 re-read 2 minutes ago

Piperacillin/tazobactam

Developed for
asthma · bronchiectasis · Pseudomonas aeruginosa infectious disease · respiratory tract infectious disorder

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT03262142 Comparator Jan 2018 → Mar 2023 Pseudomonas aeruginosa infectious disease, asthma, bronchiectasis, respiratory tract infectious disorder Chronic Obstructive Pulmonary Disease Trial Network, Denmark Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Piperacillin/tazobactam ClinicalTrials.gov intervention name — accepted as the source's own label NCT03262142
Route Intravenous Intravenous Piperacillin/tazobactam four times daily” NCT03262142